Physician profile
John Morrison
NPI 1376112078
$1,030.41
in general payments reported to CMS, 2019-2025
19 companies · $858 in 2025
The $858 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.43 · 2023: $37.67 · 2024: $93.26 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $262.57 | 2025 | |
| Lilly USA, LLC | $155.47 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Arteriocyte Medical Systems, INC. | $122.70 | 2025 | Magellan |
| Pfizer INC. | $121.53 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $65.20 | 2025 | Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $47.75 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $36.92 | 2021-2024 | |
| Amgen INC. | $32.88 | 2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $21.65 | 2025 | Arexvy, Shingrix |
| Biogen, INC. | $19.68 | 2025 | Zurzuvae |
| Csl Behring | $19.06 | 2021 | |
| Hologic Sales and Service, LLC | $18.78 | 2025 | Myosure Tissue Removal Device |
| Takeda Pharmaceuticals U.S.A., INC. | $17.89 | 2024 | Trintellix |
| Urogen Pharma, INC. | $17.50 | 2023 | Jelmyto |
| Merck Sharp & Dohme LLC | $15.46 | 2025 | Capvaxive, Enflonsia, Vaxneuvance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $15.39 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.34 | 2024 | Jardiance |
| Exact Sciences Corporation | $13.56 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $11.08 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.